Loading...
XSHE
002923
Market cap514mUSD
Jul 10, Last price  
10.67CNY
1D
2.40%
1Q
-18.86%
IPO
29.75%
Name

Zhuhai Rundu Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002923 chart
P/E
P/S
3.04
EPS
Div Yield, %
1.44%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
-0.23%
Revenues
1.18b
-0.51%
311,179,689361,933,893434,131,304523,598,200577,942,780651,862,100779,421,0161,043,860,4651,043,860,4651,359,908,2941,252,630,8361,189,926,8671,189,926,8671,372,233,9171,372,233,9171,291,887,1411,182,362,7671,176,361,072
Net income
-63m
L
32,211,69356,596,23159,359,21459,519,86371,165,38387,465,80290,652,618106,844,362106,844,366118,896,732135,862,414139,766,332139,766,338155,476,936155,476,93966,898,62239,883,174-63,472,073
CFO
104m
-50.56%
33,710,09170,013,89831,674,10058,011,47650,138,96794,069,92257,952,639159,043,847151,299,880250,346,177205,906,013135,007,685172,679,270211,187,476104,405,514
Dividend
May 30, 20250.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhuhai Rundu Pharmaceutical Co., Ltd., a pharmaceutical firm established in 1997 and based in Zhuhai, China, is engaged in the research, production, and worldwide distribution of pharmaceutical components. The company's diverse portfolio of medicinal ingredients targets key therapeutic areas such as cardiovascular health, gastrointestinal conditions, central nervous system (CNS) disorders, and anesthesia. Its offerings include Active Pharmaceutical Ingredients (APIs), intermediate compounds, finished dosage forms (FDFs), and pellets, which are supplied in common formats like capsules, tablets, and injectable solutions.
IPO date
Jan 05, 2018
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122019‑002018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT